Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991
1991
Platinum Compounds in Cancer Treatment
Commentary
Author Information
Author(s): M.J. McKeagel, J.D. Higgins II, L.R. Kelland
Primary Institution: The Institute of Cancer Research
Conclusion
Recent advances in platinum drug development show promise in overcoming cisplatin resistance in cancer treatment.
Supporting Evidence
- New platinum complexes are being developed to avoid resistance seen with cisplatin.
- Orally active platinum drugs are showing promise in preclinical studies.
- Research is ongoing to understand the mechanisms of cisplatin resistance.
Takeaway
Scientists are working on new platinum drugs to help treat cancer, especially for patients who don't respond to the usual treatment.
Methodology
The commentary summarizes findings from a symposium on platinum compounds in cancer treatment, focusing on synthetic chemistry, biochemical pharmacology, and clinical trials.
Limitations
The trials discussed are at early stages, limiting conclusions about clinical utility.
Want to read the original?
Access the complete publication on the publisher's website